Development of AZD5363, an inhibitor of AKT with activity in tumours containing mutations in the P13K-AKT pathway


Dr Barry Davis, AstraZeneca

Date & Time:

Monday, 2 November 2015, 11:00

Old Road Campus Research Building, 71A, B and C, Headington OX3 7DQ
Department of Oncology
About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.